Evidence map›Paper›PMID 41145665›Full record

ArticleNature methods2025

Improved reconstruction of single-cell developmental potential with CytoTRACE 2.

Minji Kang, Gunsagar S Gulati, Erin L Brown, Zhen Qi, Susanna Avagyan, Jose Juan Almagro Armenteros, Rachel Gleyzer, Wubing Zhang, Chloé B Steen, Jeremy Philip D'Silva and 4 more

Abstract read
In one paragraph

Article in Nature methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. TH/TRs-COL11A2 Axis Mediates Loss of a Differentiated Astrocyte State in Hypogyrified Brains.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Minji Kang *Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0009-4249
Gunsagar S Gulati *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2798-6220
Erin L Brown *Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0004-3487
Zhen Qi *Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0009-0008-8793-9884
Susanna AvagyanDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA.
Jose Juan Almagro ArmenterosInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Rachel GleyzerInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Wubing ZhangInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Chloé B SteenDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
Jeremy Philip D'SilvaInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0009-0005-0053-7726
Janella SchwabInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3784-9174
Michael F ClarkeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6889-4926
Aadel A ChaudhuriDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-3115-3061
Aaron M NewmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. amnewman@stanford.edu.ORCID http://orcid.org/0000-0002-1857-8172

Funding

Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNAR01CA283317 · NCI · MAYO CLINIC ROCHESTER · PI Aadel Chaudhuri, Aaron M Newman · 2024 to 2026
$3.4M
Delineating developmental programs driving tumorigenesis in triple-negative breast cancerR01CA255450 · NCI · STANFORD UNIVERSITY · PI NEWMAN, AARON M · 2021 to 2025
$2.5M
Kirke-, Utdannings- og Forskningsdepartementet (Norwegian Ministry of Education, Research and Church Affairs) 334328National Science Foundation (NSF) DGE-1656518NCI NIH HHS R01 CA255450NCI NIH HHS R01 CA283317NCI NIH HHS T32 CA009302U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA255450U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA283317V Foundation for Cancer Research (V Foundation) V Scholar Award
6 · The paper itself

Abstract

While single-cell RNA sequencing has advanced our understanding of cell fate, identifying molecular hallmarks of potency-a cell's ability to differentiate into other cell types-remains a challenge. Here we introduce CytoTRACE 2, an interpretable deep learning framework for predicting absolute developmental potential from single-cell RNA sequencing data. Across diverse platforms and tissues, CytoTRACE 2 outperformed previous methods in predicting developmental hierarchies, enabling detailed mapping of single-cell differentiation landscapes and expanding insights into cell potency.

Indexed as

Cell DifferentiationDeep LearningSequence Analysis, RNASingle-Cell AnalysisAnimalsHumansMiceRNA-Seq

Identifiers

PMID41145665
PMCPMC12615260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.